Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide monotherapy in Chinese patients with type 2 diabetes
NCT05963022Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2023
- Primary completion
- Oct 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tirzepatide in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Hemoglobin A1c at 40 weeks. Started Aug 2023; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05963022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05963022.